Zurich-Schlieren, Switzerland, April 27, 2023. Proteomedix, a Swiss diagnostics company committed to advance prostate cancer care, today announced that Proclarix® has been included in the 2023 clinical practice guideline for the early detection of prostate cancer of the American Urology Association (AUA), in partnership with the Society of Urologic Oncology (SUO).
Shortly after the inclusion in the European Association of Urology (EAU) guideline, Proclarix was also included in the 2023 clinical practice guideline of the AUA/SUO. The guideline covers recommendations on the early detection of prostate cancer and provides a framework to facilitate clinical decision-making in the implementation of prostate cancer screening, biopsy, and follow-up.
Dr. Ralph Schiess, Chief Scientific officer and co-founder of Proteomedix commented: “The inclusion of Proclarix in the AUA/SUO guideline is in line with our strategy of making the test also available in the US. It further validates the clinical value of Proclarix and its use in decision-making if a biopsy is necessary.”
The AUA/SUO guideline concludes that the evaluation of prostate cancer risk should be focused on the detection of clinically significant prostate cancer (grade group 2 or higher [GG2+]). The use of laboratory biomarkers such as Proclarix, prostate MRI, and biopsy techniques may improve detection and safety when a prostate biopsy is deemed necessary following prostate cancer screening.
Proclarix® is CE-certified under IVDR and indicated for prostate cancer diagnosis in patients with normal digital rectal exam (DRE), enlarged prostate volume and elevated levels of PSA at 2-10 ng/ml. Proclarix is a risk score combining in-vitro assays for the quantitative detection of biomarkers with a proprietary algorithm to assess a patient’s risk of having clinically significant prostate cancer. Detection of prostate cancer-related biomarkers in blood serum using the Proclarix risk score has been demonstrated in multiple clinical studies to be a reliable indicator of the presence of clinically significant prostate cancer.
Proteomedix is a healthcare company whose mission is to transform prostate cancer diagnosis. The company has identified novel biomarker signatures with utility in prostate cancer diagnosis, prognosis and therapy management. The lead product Proclarix® is a blood based prostate cancer test panel and risk score currently available in Europe. Proteomedix is located in the Bio-Technopark of Zurich-Schlieren, Switzerland. For more information, visit www.proteomedix.com.
For further details, please contact:
Dr. Ralph Schiess, CSO
email@example.com, +41 44 733 40 90